Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Patient Support Specialist Job
Celgene Corporation - Berkeley Heights, NJ, US
Clinical Research Coordinator
Lovelace Respiratory Research Institute - Albuquerque, NM

More Jobs >>

Events

New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
CHI's Summit for Clinical Ops Executives (Scope)
February 7-9 — Miami

More Events >>

Related Tags >> Vaccine Celldex Therapeutics oncology

3M News

Most Popular 3M Story

Celldex inks tech deal to advance cancer vaccines

June 12, 2008 — 7:06am ET | By John Carroll

Celldex Therapeutics has struck a deal to use 3M's toll-like receptor (TLR) agonist compounds--useful as vaccine adjuvants--for a slate of new oncology vaccines in development. 3M Drug Delivery Read more...

3M Press Releases

3M Drug Delivery Systems Signs Licensing Agreement with Spirig Pharma AG

Latest Headlines

Celldex inks tech deal to advance cancer vaccines
June 12, 2008

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK